Annual cashflow statement for Neurogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60.7 | -57.6 | -36.3 | -75.1 | -90.4 |
| Depreciation | |||||
| Non-Cash Items | 12.5 | 9.5 | -14.3 | 7.31 | 9.87 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.7 | 0.885 | -4.02 | -5.96 | 0.268 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -47.6 | -45.6 | -51.4 | -70.6 | -77.2 |
| Capital Expenditures | -3.26 | -1.11 | -0.321 | -0.808 | -1.18 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -58 | 26 | -124 | 15.2 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.26 | -59.1 | 25.6 | -125 | 14 |
| Financing Cash Flow Items | 0 | — | — | 182 | -0.241 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.732 | 0.161 | 92.5 | 184 | 30.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -50.1 | -105 | 66.7 | -11.8 | -32.7 |